NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equipment

Equipment

9 Months Ended

Jun. 30, 2022

Equipment

Equipment

4. Equipment

The Company’s equipment consisted of the following:


	As of June 30,		As of September 30,
	2022		2021
Laboratory equipment	$	3,182,369	$	2,737,390
Office equipment		259,978		259,978
Leasehold improvements		10,128		—
Total		3,452,475		2,997,368
Accumulated depreciation		(1,101,189)		(533,486)
Property, plant and equipment, net	$	2,351,286	$	2,463,882

Depreciation expense for the three months ended June 30, 2022 and 2021 was approximately $0.2 million and $0.1 million, respectively. Depreciation expense for the nine months ended June 30, 2022 and 2021 was approximately $0.6 million and $0.3 million, respectively.